Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06040099
Title A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)
Acronym EMERALD-Y90
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.